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FUNCTIONS OF THE HOMEOBOX GENE DLX4 IN CONTROLLING 
INFLAMMATORY SIGNALING AND METASTASIS OF EPITHELIAL OVARIAN 
CANCER 
 
Dhwani Haria, B.S. 
 
Advisory Professor: Honami Naora, Ph.D. 
 
       Epithelial ovarian cancer (EOC) accounts for the most number of deaths among women 
with gynecological malignancies in the United States. Approximately 80% of EOC patients 
are diagnosed with disease that has disseminated beyond the confines of the ovaries. The five 
year survival rate for patients with advanced stage EOC is less than 30% and the recurrence 
of chemoresistant disease is high. Identifying the mechanisms that control peritoneal 
metastasis of EOC is therefore critical for improving treatment of advanced stage disease. 
The homeobox gene DLX4 encodes a transcription factor that is absent from most normal 
adult tissues. Previous studies from our laboratory have identified that DLX4 is highly 
expressed in advanced stage EOC and is strongly associated with reduced survival. The 
underlying hypothesis of my study is that DLX4 promotes peritoneal dissemination of EOC. 
The overall goal of my study is to determine the role and mechanisms of DLX4 in controlling 
peritoneal metastasis of EOC. My specific aims are: 1) to determine whether DLX4 promotes 
peritoneal dissemination of EOC, and 2) to identify the mechanisms by which DLX4 controls 
tumor–peritoneum interactions. Firstly, my studies have identified that DLX4 promotes EOC 
dissemination by inducing expression of the cell adhesion molecule CD44 which is a major 
vi 
 
receptor for hyaluronan, a glycosaminoglycan that is expressed on mesothelial cells lining 
the peritoneal cavity and abdominal organs. Secondly, my studies have identified that DLX4 
induces CD44 expression by activating the pro-inflammatory cytokine interleukin 1-beta (IL-
1β) which in turn stimulates the nuclear factor kappa B (NF-κB) signaling pathway. This 
study provides insights into the mechanisms of peritoneal metastasis of EOC and raises the 
possibility that targeting inflammatory signaling could be a strategy for treatment of 
advanced stage EOC.  
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CHAPTER 1: INTRODUCTION 
A. BIOLOGY OF OVARIAN CANCER 
1. Classification and Clinical Staging of Ovarian Cancer 
       Ovarian cancer accounts for the highest lethality among women with gynecologic 
malignancies in the United States 
1
. Ovarian cancers are classified as 1) epithelial tumors, 2) 
sex cord stromal tumors and 3) germ cell tumors. Epithelial ovarian cancers (EOC) constitute 
about 60% of all ovarian tumors and 90% of malignant tumors 
2
. It has been traditionally 
thought that EOC originates from the ovarian surface epithelium. However, recently, the 
fallopian tube and some other epithelial tissues have been reported as origins for EOC 
3, 4
. 
EOC is a heterogeneous disease and is categorized into different subtypes based on their 
histologic features 
2
. These histologic subtypes exhibit different types of mutations (Table 1). 
The serous subtype is the most common form of EOC (Figure1) 
5, 6
. The stage of the disease, 
i.e. its spread within the ovaries or to other parts of the body is evaluated during surgery 
(Table 2) 
7
. Due to a lack of distinctive symptoms and specific diagnostic biomarkers, more 
than 60% of EOC patients are diagnosed with disease that has already spread throughout the 
peritoneal cavity (Figure 2) 
8
. In contrast, only 15% of EOC patients present with ovarian-
confined disease at the time of initial diagnosis (Figure 2) 
8
. The five-year survival rate for 
women with advanced-stage EOC is less than 30% as compared to over  90% for women 
with localized disease (Figure 2) 
8
. The majority of patients with advanced-stage EOC who 
undergo tumor-debulking surgery and conventional platinum-taxane chemotherapy relapse 
within 18 months 
9
.   
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Table 1: Common mutations identified in the histologic subtypes of EOC 
 
 
Histologic subtype 
 
Mutations 
 
 
References 
 
 
 
 
 
Serous 
 
High grade serous: 
TP53 
CDKN2A 
BRCA1/2 
Low grade serous: 
BRAF 
KRAS 
ERBB2 
 
 
 
 
 
 
10-12
 
 
 
 
Endometrioid 
 
CTNNB1 
PIK3CA 
PTEN 
ARID1A 
 
 
 
 
5, 13
 
 
 
Mucinous 
 
 
KRAS 
 
 
5, 14
 
 
 
Clear cell 
 
HNF1B 
PTEN 
ARID1A 
PIK3CA 
 
 
 
5, 15-17
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Figure 1. Relative frequencies of subtypes of EOC 
Relative frequencies of subtypes of EOCs as reported by two independent studies 
5, 6
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Table 2: International Federation of Gynecology and Obstetrics (FIGO) staging of 
EOC
7
 
 
 
FIGO Stage 
 
Characteristics of the tumor 
 
I 
 
Tumor is confined to the ovaries 
 
II 
 
 
Tumor involves one of both ovaries with extension and/or 
implantation on pelvic organs e.g. uterus and/or fallopian tubes 
 
III 
 
Tumor involves one or both ovaries with disease that has spread to 
the peritoneum outside the pelvis and/or to retroperitoneal lymph 
nodes 
 
IV 
 
Distant metastases to liver, spleen and extra-abdominal organs 
with development of pleural effusions 
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Figure 2. Stage distribution of EOC and five-year survival rate by stage 
8
. 
(A) Percentage of EOC cases by tumor stage as reported by SEER, where localized disease 
corresponds to FIGO Stage I, regional disease corresponds to FIGO stage II and distant 
disease corresponds to FIGO Stages III and IV. (B) Five-year survival rate by tumor stage. 
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Currently, the most commonly used biomarker for EOC is the glycoprotein cancer 
antigen-125 (CA-125) 
18
. Serum levels of CA-125 are found to be elevated in approximately 
80% of advanced-stage EOC cases and is used for post-operative monitoring 
18, 19
. However, 
measurement of CA-125 is not highly sensitive for detection of early stage EOC. CA-125 
levels are also elevated in other conditions such as pregnancy, endometriosis, menstruation 
and other malignancies like pancreatic, breast, lung, and gastric cancers 
20
. There is, 
therefore, a critical need for the identification of novel diagnostic biomarkers for early 
detection of EOC and new molecular targets for effective treatment against highly metastatic 
and chemoresistant EOC.  
2. Biology of dissemination of EOC 
       Unlike most other types of solid tumors, EOC does not typically metastasize via 
lymphatic or hematogenous routes 
21
. In the initial stage, the tumor is confined to one or both 
the ovaries. As the disease progresses, the ovarian capsule is disrupted and the tumor first 
spreads by directly extending to adjacent organs, for example, uterus and fallopian tubes 
(Figure 3) 
22
. Distal dissemination of EOC occurs primarily via intraperitoneal seeding 
(Figure 4). Exfoliated tumor cells are transported by the circulating peritoneal fluid and 
undergo implantation on the mesothelial linings of the peritoneal cavity wall and abdominal 
organs (Figures 3,4) 
22
. This peritoneal carcinomatosis is commonly associated with 
formation of ascites 
22
. 
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Figure 3. Pattern of spread of EOC 
In the early stage, the tumor (shown as red masses) is confined to one or both the ovaries. 
Once the ovarian capsule is disrupted, the tumor spreads by direct extension to adjacent 
organs. Exfoliated tumor cells are then transported by the circulating peritoneal fluid and 
implant on the mesothelial linings of the pelvic cavity wall and abdominal organs. The 
omentum is the most common implantation site 
22
. 
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Figure 4. Model of peritoneal seeding of EOC 
Distal spread of EOC cells (shown in red) occurs via ‘seeding’ of the peritoneal cavity. EOC 
cells are exfoliated into the peritoneal fluid and form multicellular aggregates to escape 
anoikis. Surviving EOC cells are transported by the circulating peritoneal fluid and then 
implant on the mesothelial linings of the peritoneal cavity 
22
.  
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2.1. Implantation of EOC cells on to the peritoneum  
       The ability of EOC cells to ‘seed’ the peritoneal cavity is a hallmark of this disease. The 
attachment of EOC cells to the peritoneal surfaces is a key rate-limiting step. It is thought 
that attachment of EOC cells to the peritoneum is mediated via two primary mechanisms: 1) 
attachment to the mesothelial cells lining the peritoneal cavity and 2) attachment to the sub-
mesothelial extracellular matrix (ECM) 
23-26
. Mesothelial cells, that are derived from the 
mesoderm, form a monolayer that lines the surface of body’s three serosal cavities: pleural, 
pericardial and peritoneal 
27
. The mesothelial cell lining functions as a protective layer and a 
non-adhesive surface that facilitates movement of other tissues and plays an essential role in 
immune and inflammatory responses 
27
. Attachment of EOC cells to mesothelial cells is 
mediated by a repertoire of ligands and receptors. The EOC biomarker CA-125 can mediate 
tumor cell implantation by binding the glycosylphosphatidyl inositol (GPI)-linked protein 
mesothelin that is expressed on mesothelial cells 
28, 29
. Integrins are cell surface protein 
complexes composed of α and β subunits that have been reported to facilitate attachment of 
EOC cells to mesothelial cells and also to the sub-mesothelial ECM 
30
. Several groups have 
demonstrated that β1 integrin mediates binding of EOC cells to peritoneal mesothelial cells 
31-33
. On the other hand, several studies have reported that integrins such as β1 and αvβ3 
promote EOC metastasis by binding to components of the ECM such as collagen type, 
fibronectin, laminin and vitronectin 
34-37
. A study by Iwanicki and colleagues demonstrated 
that spheroids of EOC cells can gain access to the sub-mesothelial ECM by displacing 
mesothelial cells that line the peritoneal organs by utilizing myosin-generated traction force 
that is dependent on activation of α5β1 integrin and talin I 38.  
10 
 
       Cadherins constitute a gene super-family of membrane glycoproteins that facilitate cell-
cell adhesion via homophilic interactions. Substantial evidence indicates that alteration in 
cadherin expression, often termed ‘cadherin switching’ drives tumor progression 39, 40. The 
most well-characterized form of cadherin-switching involves upregulation of N-cadherin and 
P-cadherin and downregulation of E-cadherin 
39, 40
. Loss of E-cadherin expression and 
increase in expression of N-cadherin in advanced stage EOC correlates with poor prognosis 
in patients 
41
. High expression of P-cadherin has also been found to correlate with reduced 
overall survival of EOC patients 
41
. P-cadherin facilitates formation of multi-cellular 
aggregates of EOC cells, inhibits anoikis and also promotes attachment of EOC cells to 
peritoneal mesothelial cells 
42
.  
       The most-studied cell adhesion molecule that promotes attachment of EOC cells to the 
mesothelial lining is the cell-surface glycoprotein CD44. CD44 proteins are encoded by a 
highly conserved gene and are present in different isoforms 
43
. This heterogeneity among the 
different isoforms is due to differential glycosylation and alternative splicing of exons 
43
. The 
smallest isoform CD44s is the most common isoform and is present on the membrane of 
most vertebrate cells. However, unlike CD44s, variant isoforms of CD44 are only expressed 
on some epithelial cells during embryogenesis, lymphocytes and in certain cancers 
44, 45
. 
CD44v7 has been reported to promote metastasis of pancreatic adenocarcinomas 
46
. Another 
study reported that CD44v6 interacts with vascular endothelial growth factor-A (VEGF-A) 
and hepatocyte growth factor (HGF) to promote tumor angiogenesis 
47
. Standard and variant 
isoforms of CD44 have been detected in EOCs 
48
. Expression of CD44s in EOC is an 
independent predictor of survival and its expression correlates with poor outcomes and 
decreased overall survival 
49-51
. CD44 is a major receptor for the glycosaminoglycan, 
11 
 
hyaluronic acid (HA) that is synthesized by mesothelial cells lining the peritoneal cavity 
52, 53
. 
CD44 facilitates attachment of EOC cells to peritoneal mesothelial cells by binding to HA 
24, 
53, 54
. A study by Strobel and colleagues demonstrated that a CD44 neutralizing antibody (Ab) 
significantly inhibited EOC cell implantation on peritoneal mesothelial linings in 
intraperitoneal (i.p.) xenograft models 
55
. However, the mechanisms that induce expression 
of CD44 in EOC cells are poorly understood and require further investigation.  
2.2. Inflammatory signaling in EOC 
       A second hallmark of EOC is the formation of ascites 
56
. Accumulation of fluid in the 
peritoneal cavity stems from increased vessel permeability 
57, 58
. VEGF-A is widely 
recognized as the causative factor of ascites formation. High levels of VEGF-A have been 
demonstrated to induce vascular permeability and stimulate formation of ascites in EOC 
59-62
. 
Ascitic fluid contains a wide range of growth factors, inflammatory cytokines and 
chemokines that function via autocrine and paracrine mechanisms and promote tumor 
progression 
63
. Pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8), 
interleukin-10 (IL-10) and interleukin-1β (IL-1β) are present in ascites of EOC patients and 
are associated with poor outcomes in patients 
64
. IL-6 promotes EOC cell growth and also 
stimulates chemoresistance and tumor angiogenesis 
65-68
. Elevated levels of IL-8 also 
promote angiogenesis in EOC 
69
. Elevated levels of IL-1β in ascites of EOC patients 
significantly correlate with poor histopathological grade and reduced progression-free 
survival 
70
. Normal and malignant EOC cells as well as activated stromal immune cells are 
the major sources of IL-1β 71. Constitutive secretion of IL-1β by EOC cells promotes tumor 
invasion by inducing expression of matrix metalloproteinase-1 (MMP-1) and tumor 
angiogenesis by stimulating production of VEGF 
72, 73
. IL-1β promotes inflammatory 
12 
 
signaling in tumors via activation of nuclear factor kappa B (NF-κB) signaling pathway 74. 
Secretion of IL-1β by EOC cells downregulates expression of p53 in stromal fibroblasts and 
stimulates NF-κB signaling which in turn leads to an increase in the expression of other 
molecules such as IL-8, IL-6 and VEGF 
75
. However, the mechanisms by which IL-1β 
promotes peritoneal metastasis of EOC are not clear. 
2.3. NF-κB signaling in EOC 
       The NF-κB signaling pathway is activated in many types of tumors. A central 
component of the pathway comprises a family of five transcription factors: p50, p52, p65 
(RelA), c-Rel and RelB 
76
. There are two different pathways for activation of NF-κB 
signaling: canonical and non-canonical. The canonical signaling pathway is triggered by 
microbial products and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) 
and IL-1 leading to activation of RelA or c-Rel, which form dimers with p50 
77
. The dimers 
interact with inhibitors of NF-κB family of proteins (IκBα, IκBβ, and IκBε) in the cytoplasm 
and are in an inactive state. When the canonical pathway is triggered, the IκB proteins get 
phosphorylated by the IκB kinases (IKKs) on conserved serine residues and in turn IκB 
proteins undergo degradation by the ubiquitin-proteasome pathway and release the NF-κB 
dimers. The dimers then translocate to the nucleus and function as transcription factors to 
activate target genes (Figure 5) 
77
. The non-canonical signaling pathway is activated by TNF-
family cytokines like B-cell activating factor (BAFF), lymphotoxin B, CD40 ligand (CD40L) 
and receptor activator of NF-κB ligand (RANKL), which results in the activation of 
RelB/p52 complexes. Whereas the canonical pathway is typically regulated by the IKKβ and 
IKKγ subunits, the non-canonical pathway is regulated by IKKα which phosphorylates and 
processes p100, the precursor form of p52 (Figure 5) 
77, 78
. Although NF-κB signaling is 
13 
 
widely activated in solid tumors, there are no known oncogenic mutations in members of the 
NF-κB family. The activation of this pathway, therefore, has largely been attributed to 
inflammatory signals in the tumor microenvironment 
79
.  
       The ovarian tumor microenvironment contains a wide variety of pro-inflammatory 
cytokines that are secreted by tumor cells and stromal cells. High levels of TNF-α, IL-1α, IL-
1β and IL-6 have been detected in EOC tissues as compared to levels in normal ovarian 
tissues 
80-82
. Several studies have demonstrated that high levels of cytokines such as TNF-α 
and IL-1β in EOC promote tumor progression by activation of NF-κB signaling 75, 83. For 
example, a study by Kulbe and colleagues identified that TNF-α, through its activation of 
NF-κB, upregulates expression of the chemokine receptor CXCR4 which in turn interacts 
with its ligand CXCL12, and promotes increased tumor growth and migration 
83
. Activation 
of the NF-κB pathway in turn induces downstream target genes that encode ligands that 
activate the pathway such as TNF-α and IL-1β, and also other target genes encoding IL-6, IL-
8, VEGF and MMPs 
74
. This NF-κB signaling loop leads to activation of chronic signaling in 
tumors. A number of independent studies have demonstrated a strong association between 
activation of NF-κB transcription factors in EOC and poor outcomes in patients 84, 85. Higher 
expression of NF-κB transcription factors such as p50 and p65 has been detected in 
advanced-stage EOCs as compared to borderline and benign tumors or normal ovaries 
85
. 
Levels of phosphorylated p65 in EOC strongly correlate with advanced disease stage and 
high tumor grade 
86, 87
. However, the mechanisms by which chronic NF-κB signaling 
promotes peritoneal dissemination of EOC are poorly understood. 
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Figure 5: NF-κB signaling pathway 
The canonical NF-κB signaling pathway is triggered by proinflammatory cytokines such as 
TNF-α and IL-1β whereas the non-canonical NF-κB signaling pathway is triggered by 
cytokines such as lymphotoxin B, CD40L, BAFF and RANKL. These signals lead to 
activation of the IKK complex (shown in blue). In the canonical pathway, the IKK complex 
phosphorylates IκB (shown in green) at two serine residues, which signals it for degradation 
and release of the phosphorylated NF-κB dimers (shown in orange). The NF-κB dimers then 
translocate to the nucleus and induce transcription of target genes 
88
. Activation of the IKK 
complex in the non-canonical pathway leads to phosphorylation and degradation of p100, 
releasing p52-RelB heterodimers (shown in yellow). The heterodimers then translocate to the 
nucleus and activate transcription of target genes 
89
. 
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B. HOMEOBOX GENES 
1. General overview of homeobox genes 
       Homeobox genes consist of a large super-family of approximately 200 vertebrate genes 
that play essential roles in body plan specification and development of virtually all organ 
systems during embryogenesis 
90, 91
. In adults, homeobox genes regulate tissue homeostasis 
and regeneration, differentiation of hematopoietic progenitors and vascular remodeling 
92, 93
. 
Homeobox genes were first identified due to their mutations in Drosophila that caused 
formation of body segments in the wrong context. For example, loss-of-function mutations in 
the Antennapedia gene in Drosophila results in development of ectopic antennae instead of 
legs 
94
. Similarly, in humans, aberrant expression of homeobox genes can cause 
developmental defects like malformation of limbs or other sensory defects 
95, 96
. Homeobox 
genes encode proteins termed ‘homeoproteins’ that primarily function as transcription factors 
97, 98
. Homeoproteins consist of a highly conserved DNA binding domain that is known as the 
‘homeodomain’. This homeodomain forms three alpha-helices which binds DNA elements 
having TAAT core motifs (Figure 6) 
99
.   
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Figure 6. Structure of the homeodomain 
Transcription factors encoded by homeobox genes consist of a highly conserved 61 amino 
acid DNA binding domain termed the ‘homeodomain’. The homeodomain forms three α-
helices (colored boxes) that bind DNA elements containing TAAT core motifs 
99
. 
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2. Genomic organization of homeobox genes 
       In mammals, homeobox genes are classified into different families based on the 
similarities in their homeodomains and functional motifs 
100
. Mammalian homeobox gene 
families are named after their homologs in Drosophila. For example, members of the 
mammalian gene families DLX, CDX, and OTX are named after homologous Drosophila 
gene families distal-less, caudal, and orthodenticle respectively 
101
. Eventhough many 
homeobox genes in mammals are dispersed throughout the genome, members of HOX and 
DLX gene families are arranged in clusters 
102, 103
. The 39 members of the mammalian HOX 
gene family are grouped in clusters on four different chromosomes (Figure 7) 
104, 105
. 
Likewise, the six members of the mammalian DLX gene family are arranged in bigene 
clusters and are located upstream of the HOX gene clusters (Figure 7) 
105, 106
. It has been 
postulated that clusters of HOX and DLX gene families derived from gene duplication during 
evolution 
103, 107
.  
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Figure 7. Clusters of HOX and DLX gene families 
The 39 members of the mammalian HOX gene family are organized in clusters on 4 different 
chromosomes. The 6 members of the DLX gene family are arranged in bigene clusters, 
located upstream of the HOX loci  
105, 106
.  
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3. Deregulation of homeobox genes in tumors 
       Substantial evidence indicates that expression of several homeobox genes is deregulated  
in a wide variety of tumors 
97
. Deregulation of homeobox genes in cancer falls into two broad 
categories. The first category of homeobox genes are those that are usually expressed only in 
normal, differentiated adult tissues but are often downregulated in tumors and have tumor 
suppressive functions (Figure 8) 
97, 99, 101
. Loss of expression of these homeobox genes has 
been attributed to epigenetic mechanisms, long non-coding RNAs and chromosomal 
aberrations like loss of heterozygosity 
101
. For example, loss of HOXA5 in breast cancers 
occurs due to promoter hypermethylation 
108
. Loss of HOXA5 results in a down-regulation of 
p53 expression and tumor progression in breast cancers 
108
. The long non-coding RNA 
HOTAIR which is located in the HOXC locus binds to and re-targets Polycomb Repressive 
Complex 2 (PRC2), a large multi-protein complex that mediates transcriptional silencing 
109, 
110
. HOTAIR re-targets the PRC2 complex to the HOXD locus 
109
. In breast cancers, 
increased expression of HOTAIR in primary tumors is considered to be highly predictive of 
metastatic disease and poor outcomes 
109
. The homeobox gene NKX3.1, which maps to 
chromosomal region 8p21, is expressed in fetal and adult prostate tissues and controls normal 
differentiation of prostatic epithelium 
111, 112
. Loss of heterozygosity of NKX3.1 occurs in 
approximately 60%-80% of prostate cancers 
113
. Loss of NKX3.1 induces development of 
prostatic intraepithelial neoplasia (PIN) 
114
. Furthermore, loss of NKX3.1 coupled with loss of 
the tumor suppressor gene PTEN and overexpression of oncogene c-myc promotes prostate 
cancer progression 
115-118
. 
       The second category of homeobox genes are those that are usually expressed in 
embryonic tissues but not in adult tissues. These homeobox genes are often upregulated in 
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tumors and have tumor promoting functions (Figure 8) 
97, 99, 101
. Gain of function of 
homeobox genes in tumors can be caused by chromosomal aberrations like gene 
amplification 
101
. For example, the HOXB gene cluster and the homeobox gene DLX4 map to 
the 17q21.3-q22 region, a chromosomal hotspot amplified in about 10% of breast cancers 
and EOC 
119-121
. HOXB7 is also overexpressed in various other types of tumors such as 
pancreatic cancer, colorectal cancer and melanomas 
122-124
. High expression of HOXB7 in 
breast cancers, EOC and melanomas drives tumor progression in part by activating 
transcription of the gene that encodes basic fibroblast growth factor (bFGF) 
122, 125-127
. 
HOXB7 also promotes resistance to tamoxifen in breast cancers by inducing expression of 
epidermal growth factor receptor (EGFR) and its ligands, thereby activating EGFR signaling 
128
. HOXB7 and DLX4 are over-expressed in more than 50% of breast cancers and EOC 
though only 10% of cases exhibit a loss of the chromosomal region containing the gene 
cluster 
129, 130
. This highlights the need to identify more mechanisms of homeobox gene 
deregulation as well as downstream transcriptional targets that will aid in developing better 
targeted therapies.  
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Figure 8. Trends in the aberrant expression of homeobox genes in tumors  
Homeobox genes that are normally expressed only in embryonic tissues are often activated in 
tumors and generally have tumor-promoting functions (shown in orange). Homeobox genes 
that are normally expressed in normal differentiated adult tissues are down-regulated in 
tumors and generally have tumor-suppressive functions (shown in yellow) 
101
.  
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Table 3: Examples of significance of aberrant homeobox gene expression in tumors  
 
Homeobox 
gene 
 
Type of cancer 
 
Expression 
pattern 
in tumors 
 
Functional significance of 
deregulation in tumors 
 
References 
 
 
HOXB7 
 
melanoma, breast, 
pancreatic, 
colorectal, ovarian 
  Induces expression of EGFR 
and FGF2  
 Promotes tumor growth and 
angiogenesis 
 Promotes EMT and 
chemoresistance 
 
 
122-128
 
 
 
HSIX1 
 
breast, 
pancreatic, 
rhabdomyosarcomas 
  Promotes tumor growth by 
inducing cyclin A1 
 Promotes lymphangiogenesis 
and metastasis by inducing 
VEGF-C and ezrin expression  
 
 
131-135
 
 
 
 
HOXA9 
 
 
ovarian, 
glioblastomas 
 
  Promotes EOC growth by 
stimulating cancer-associated 
fibroblasts and macrophages 
with immunosuppressive 
properties 
 Promotes EOC dissemination 
via induction of P-cadherin  
  
 
 
136-139
 
 
 
NKX3.1 
 
 
prostate 
  Loss of NKX3.1 causes PIN-
like lesions in mice 
 Co-operates with loss of PTEN 
to induce prostate cancer 
progression  
 
 
114, 116-118
 
 
 
 
HOXA5 
 
 
 
breast 
  Loss of HOXA5 promotes cell 
cycle deregulation and 
metastasis by inducing loss of 
p53 and promoting expression 
of Twist 
 Loss of HOXA5 induces 
genomic instability by down-
regulating expression of human 
MutL homolog 1 (hMLH1) 
 
 
 
108, 140, 141
 
 
 
 
CDX2 
 
 
 
colorectal  
  Loss of CDX2 promotes 
genomic instability by inducing 
DNA repair via non-
homologous end joining (NHEJ) 
pathway 
 Loss of CDX2 deregulates cell 
cycle progression by down-
regulating expression of cyclin 
dependent kinase inhibitors 
p27Kip1 and p21/waf1/cip1 
  
 
 
142-144
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4. Role of the homeobox gene DLX4 in tumors 
       DLX4, a member of the DLX family of homeobox genes, is also reported as BP1, DLX7 
and DLX8 
91, 145
. DLX4 is generally expressed in endometrium, placenta, trophoblast and 
normal bone marrow cells but not in other normal adult tissues 
146-148
. Increasing evidence 
indicates that DLX4 is expressed in hematological malignancies and also solid tumors such as 
EOC, breast, prostate, and lung cancers (Table 4). Previous studies in our laboratory have 
demonstrated that high expression of DLX4 in tumors confers resistance to anti-proliferative 
signals mediated by TGF-β, promotes genomic instability and chemoresistance in various 
tumors 
149, 150
. DLX4 has been reported to promote invasiveness of breast cancer by inducing 
expression of TWIST and inhibiting expression of E-cadherin 
151, 152
. Other studies from our 
laboratory have found that DLX4 is absent from normal ovary and ovarian cystadenomas 
129
. 
On the other hand, expression of DLX4 in EOC strongly correlates with advanced disease 
stage, high tumor grade and reduced overall survival of patients 
129
. The ability of DLX4 to 
promote EOC growth has been attributed in part to its stimulation of tumor angiogenesis 
129
. 
However, the mechanisms by which DLX4 promotes EOC metastasis are poorly understood.  
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Table 4: Examples of aberrant expression and functional significance of DLX4 in 
tumors 
 
Type of cancer 
 
Pattern of DLX4 
expression in 
cancers 
 
Functional significance of 
deregulation of DLX4 in cancers 
 
References 
 
 
Breast 
 
 
Overexpressed in 
80% of breast 
cancers 
 
 Represses BRCA1 expression 
 Upregulates Twist and promotes 
tumor metastasis  
 Promotes tumor cell survival by 
inducing Bcl-2 and inhibiting 
apoptosis 
 
 
130, 151-157
 
 
 
Ovarian 
 
Overexpressed in 
~50% of EOC and 
correlates with 
advanced disease 
stage and high tumor 
grade 
 
 Promotes tumor angiogenesis 
by inducing expression of 
VEGF and bFGF 
 
129
 
 
 
Prostate 
 
Overexpressed in 
70% of prostatic 
adenocarcinomas 
  
158
 
 
 
Choriocarcinoma 
 
Expressed in normal 
placenta and human 
choriocarcinoma cell 
lines 
 
 Promotes tumor cell survival  
 
159, 160
 
 
 
Leukemias 
 
Overexpressed in 
bone marrow of 63% 
of acute myeloid 
leukemia (AML) 
cases 
 
 Increases clonogenicity of 
leukemic cells 
 Induces expression of c-myc  
 
148, 161, 162
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C. HYPOTHESIS AND SPECIFIC AIMS 
       The high morbidity and mortality caused by EOC stems from its propensity to 
disseminate throughout the peritoneal cavity and the inability to detect the disease at an early, 
organ-confined stage. Cancer-associated ascites is enriched in growth factors and 
inflammatory cytokines that promote inflammatory signaling and peritoneal metastasis. 
However, the mechanisms by which EOC cells activate chronic inflammatory signaling and 
by which inflammatory cytokines promote metastasis are poorly understood. The overall goal 
of my study is to identify the molecular mechanisms that promote rapid metastasis of EOC.  
       Expression of the homeobox gene DLX4 in EOC has been found to be strongly 
associated with advanced disease stage and poor survival of patients. However, the 
significance of DLX4 in promoting metastasis of EOC is not known. My broad hypothesis is 
that DLX4 promotes peritoneal dissemination of EOC. Specifically, I hypothesize that DLX4 
promotes peritoneal dissemination of EOC by controlling inflammatory signaling.  
The specific aims of my study are:  
1) To determine whether DLX4 promotes peritoneal dissemination of EOC 
2) To identify the mechanisms by which DLX4 controls tumor-peritoneum interactions 
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CHAPTER 2: MATERIALS AND METHODS 
1. Antibodies 
       Sources of antibodies (Abs) were as follows: DLX4 Ab (for flow cytometry, Abcam, 
Cambridge, MA), DLX4 Ab (for chromatin immunoprecipitation, Abnova, Taipei, Taiwan), 
CD44 Ab (for flow cytometry, BD Biosciences, San Jose, CA), CD44 Ab (for neutralization, 
Abcam), phosphorylated NF-κB p65 (Ser 536) Ab (for flow cytometry, Cell Signaling 
Technology, Danvers, MA). Secondary Abs were purchased from Pierce Biotechnology, 
Rockford, IL and BD Biosciences.  
2. Plasmids 
       A human DLX4 cDNA plasmid was provided by Dr. Patricia Berg (George Washington 
University) 
162
. Flag-tagged DLX4 was subcloned into pIRES-EGFP2 vector (Clontech, Palo 
Alto, CA) 
149
. Flag-tagged DLX4 was also subcloned into the retroviral vector, pRetroQ 
(Clontech). pGFP-VRS plasmids containing non-targeting shRNA and DLX4 shRNAs were 
purchased from OriGene Technologies (Rockville, MD). IL1B cDNA was purchased from 
Origene Technologies. pGipZ lentiviral vectors containing IL1B shRNA and non-targeting 
shRNA were purchased from shRNA and the ORFeome Core Facility (University of Texas 
MD Anderson Cancer Center, Houston, TX). The NF-κB-luciferase reporter construct 
containing tandem repeats of NF-κB transcriptional response element (TRE) was purchased 
from SABiosciences (Frederick, MD). pBabe-GFP-IκBα dominant negative (IκBα-DN) 
construct was provided by Dr. William Hahn (Broad Institute of Harvard and MIT, 
Cambridge, MA; Addgene plasmid 15264) 
163
.  
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3. Cell culture 
3.1. EOC cell lines 
       The EOC cell line A2780 was provided by Dr. Gordon Mills (University of Texas MD 
Anderson Cancer Center). The EOC cell line 2008 was provided by Dr. Zahid Siddik 
(University of Texas MD Anderson Cancer Center). Both cell lines were cultured in RPMI 
1640 medium supplemented with 10% Fetal Bovine Serum (FBS), 2mM glutamine and 
penicillin-streptomycin. 
3.2. Primary human mesothelial cells 
       Cultures of primary normal human mesothelial cells were provided by Dr. Ernst Lengyel 
(University of Chicago). Mesothelial cells were obtained from normal omental tissues of 
women undergoing surgery for benign conditions 
164
. Cultures were maintained in RPMI 
1640 medium supplemented with 20% FBS, 2mM glutamine, 100 U/ml penicillin and 100 
μg/ml streptomycin.  
4. Transfection and generation of stable lines 
       For generating A2780 stable lines, the retroviral constructs containing empty vector and 
Flag-tagged DLX4 were used to transfect Ampho293 cells using Lipofectamine 2000 (Life 
Technologies, Carlsbad, CA). Viral supernatants were harvested after 48 hours and used to 
infect A2780 cells. Stable lines were selected with puromycin (0.5μg/ml). Lipofectamine 
2000 was used for transient transfections of A2780 and 2008 cells.  
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5. In vitro cell attachment assays 
       In vitro cell attachment assays were performed as described in Ko et al 
30
. Mesothelial 
cells (30,000 per well) were seeded in 96-well plates to obtain confluent monolayers. At one 
day thereafter, green fluorescent protein (GFP)-expressing EOC cells (15,000 per well) were 
seeded onto mesothelial cells and the plates were incubated at 37ºC for one hour. For 
blocking experiments, EOC cells were pre-incubated with the CD44 blocking Ab or control 
IgG at a concentration of 10μg/ml for one hour and then seeded onto mesothelial cells. 
Unattached EOC cells were removed by gently washing the wells 3 times with culture media. 
Attached EOC cells were viewed by immunofluorescence microscopy and cells were counted 
in five random 200X microscopic fields per well in three independent experiments. 
       In other experiments, plates were coated with collagen I, fibronectin or laminin (Sigma-
Aldrich, St. Louis, MO) at a concentration of 0.5μg/well and the plates were incubated at 4ºC 
overnight. Plates were then washed 2 times with phosphate-buffered saline (PBS) and GFP-
expressing EOC cells were seeded onto coated plates and the plates were incubated at 37ºC 
for one hour. Attached cells were evaluated as described above.  
6. Flow cytometry 
       Abs were diluted in PBS containing 1% bovine serum albumin (BSA). For cell surface 
staining of CD44, tumor cells were incubated with CD44 Ab (1:10) for 30 minutes at 4°C, 
washed and incubated with peridinin-chlorophyll-protein complex (PerCP)-conjugated anti-
mouse IgG. For intracellular staining of DLX4 and phosphorylated p65, tumor cells were 
fixed in 1% paraformaldehyde (20 minutes at 4°C) and permeabilized in 0.1% saponin (15 
minutes at room temperature). Following washing, cells were incubated with Abs to DLX4 
29 
 
(1:20) and phosphorylated NF-κB p65 (1:500) for 30 minutes at 4°C, washed and incubated 
with PerCP- or phycoerythrin (PE)- conjugated secondary Abs. Staining was detected by 
flow cytometry (FACS Calibur, BD Biosciences).  
7. ELISA 
       ELISA kit for IL-1β was purchased from R&D Systems (Minneapolis, MN). Cells were 
lysed using M-PER buffer (Pierce Biotechnology) and cell lysates were prepared as per the 
manufacturer’s instructions. Intracellular IL-1β levels were assayed in the cell lysates as per 
the manufacturer’s instructions and normalized to the total cellular protein content in three 
independent experiments.  
8. Quantitative RT-PCR (qRT-PCR) 
       Total RNA was extracted from cells using PureLink RNA mini kit (Invitrogen, Carlsbad, 
CA) as per the manufacturer’s instructions. 1 μg of RNA was used to synthesize cDNA using 
qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) as per the manufacturer’s 
instructions. Transcript levels were analyzed on CFX96 Touch Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA) using primers listed in Table 5 and iTaq Universal SYBR® 
Green Supermix (Bio-Rad) as per the manufacturer’s instructions. Target gene transcript 
levels were normalized to levels of ribosomal protein RPL32. mRNA levels were assayed in 
triplicate in two independent experiments. 
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Table 5: Primers for qRT-PCR 
 
Gene 
 
Sequence 
 
 
CD44 
 
Forward 
 
5’- GGCTTTCAATAGCACCTTGC - 3’ 
 
Reverse 
 
5’- ACACCCCTGTGTTGTTTGCT - 3’ 
 
 
CDH3 
 
Forward 
 
5’- CAGGTGCTGAACATCACGGACA - 3’ 
 
Reverse 
 
5’- CTTCAGGGACAAGACCACTGTG - 3’ 
 
 
ITGB1 
 
Forward 
 
5’- GGATTCTCCAGAAGGTGGTTTCG - 3’ 
 
Reverse 
 
5’- TGCCACCAAGTTTCCCATCTCC - 3’ 
 
 
IL1B 
 
Forward 
 
 
5’- CCACAGACCTTCCAGGAGAATG - 3’ 
 
Reverse 
 
 
5’- GTGCAGTTCAGTGATCGTACAGG - 3’ 
 
 
RPL32 
 
Forward 
 
5’- ACAAAGCACATGCTGCCCAGTG - 3’ 
 
Reverse 
 
5’- TTCCACGATGGCTTTGCGGTTC - 3’ 
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9. Chromatin Immunoprecipitation (IP) 
       Chromatin IP assays were performed using EZ-ChIP Chromatin Immunoprecipitation 
Kit (Upstate Biotechnology, Temecula, CA). Cells were crosslinked by adding formaldehyde 
to a final concentration of 1% for 10 minutes at room temperature. Glycine was then added at 
room temperature for 5 minutes to quench formaldehyde. Cells were then washed twice with 
1X PBS and harvested. Cell pellets were lysed with Sodium Dodecyl Sulfate (SDS) lysis 
buffer (Upstate Biotechnology) and then sonicated to generate fragments of DNA of ~200-
1000 base pairs in length. Sheared chromatin was first pre-cleared by incubating with protein 
G agarose beads for 1 hour. Pre-cleared chromatin was then incubated with Abs to DLX4 or 
normal IgG overnight at 4°C. Protein G agarose beads were then added and incubated for 1 
hour at 4°C. The agarose-antibody/chromatin complex was washed as per the manufacturer’s 
instructions followed by elution of protein/DNA complexes, reverse crosslinking of 
protein/DNA complexes at 65°C overnight and purification of DNA using spin columns. 
Purified DNA was used to amplify fragments of the IL1B promoter by PCR. PCR products 
were analyzed on a 3% agarose gel. The primers used for PCR amplification are listed in 
Table 6. 
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Table 6: Primers for chromatin IP assays 
 
 
Gene 
 
 
Sequence 
 
 
IL1 
 
 
 
Forward 
 
5’- GGTAGAGACCCACACCCTCA - 3’ 
 
Reverse 
 
5’- CATGGAAGGGCAAGGAGTAG - 3’ 
 
GAPDH 
(Glyceraldehyde 3-
phosphate 
dehydrogenase) 
 
Forward 
 
5’- TACTAGCGGTTTTACGGGCG - 3’ 
 
Reverse 
 
5’- TCGAACAGGAGGAGCAGAGAGCGA - 3’ 
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10. Luciferase reporter assays 
       Cells were plated at a density of 1-2 x 10
5
 cells per well in 12-well plates and co-
transfected with expression plasmids (500ng/well) and NF-κB Luc or Negative Luc reporter 
plasmids (100ng/well) using Lipofectamine 2000 reagent. At 24 hours after transfection, 
luciferase activities were assayed using the Dual-reporter assay kit (Promega, Madison, WI). 
Efficiencies of transfections were normalized using Renilla luciferase readings. Relative 
luciferase activities were assayed in three independent experiments. 
11. Statistical analysis 
       Statistical significance for differences in the number of peritoneal implants in mice was 
assessed by Mann-Whitney U-Test. Statistical significance for in vitro assays was calculated 
by Student’s t-test. All statistical analyses were performed using STATISTICA10 software 
(StatSoft, Inc.). P values < 0.05 were considered significant.  
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CHAPTER 3: ROLE OF DLX4 IN PERITONEAL DISSEMINATION OF EOC 
A. RATIONALE 
       More than 60% of EOC patients are diagnosed with advanced stage disease that has 
spread throughout the peritoneal cavity 
8
. EOC cells typically spread by shedding into the 
circulating fluid that transports the cells throughout the peritoneal cavity. EOC cells then 
implant on to the mesothelial linings of the peritoneal and abdominal organs including the 
mesentery, diaphragm, omentum and cavity wall (Figures 3, 4). However, the mechanisms 
that enable implantation of EOC cells on to peritoneal surfaces are poorly understood. 
       Previous studies from our laboratory have found that the homeobox gene DLX4 is highly 
expressed in advanced stage EOC 
129
. High expression of DLX4 correlated with disease stage 
and poor survival of patients 
129
. However, the mechanisms by which DLX4 promotes 
peritoneal metastasis of EOC are not known. In this chapter, the goal of my studies is to 
determine whether DLX4 promotes peritoneal dissemination of EOC.  
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B. RESULTS 
1. DLX4 promotes implantation of EOC cells onto peritoneal surfaces in i.p. mouse 
xenograft models 
       In advanced stage disease, exfoliated EOC cells are transported by the circulating 
peritoneal fluid (Figure 4). Thereafter, these circulating EOC cells implant onto the 
mesothelial cells that line the peritoneal cavity. Nests of tumor cells are frequently observed 
on the mesentery, diaphragm and omentum of patients (Figure 3). Our laboratory has 
previously generated xenografts by i.p. inoculation of female nude mice with cells of GFP-
expressing A2780 EOC lines that stably express or lack DLX4 
129
. To initiate this study, I 
analyzed tissues of mice inoculated with vector-control A2780 cells and with DLX4-
expressing A2780 cells (+DLX4) to determine the degree of implantation of EOC cells to 
sites within the peritoneal cavity. Significantly higher numbers of implants were observed on 
the mesentery and diaphragm of mice inoculated with +DLX4 A2780 cells as compared to 
mice inoculated with equal numbers of vector-control A2780 cells (P < 0.01) (Figure 9). This 
observation raised the possibility that DLX4 promotes attachment of EOC cells to the 
mesothelial linings of the peritoneal and abdominal organs.  
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Figure 9. DLX4 increases the number of peritoneal tumor implants in i.p. mouse 
xenograft models 
Female nude mice (n=5 per group) were inoculated i.p. with 3x10
6
 cells of vector-control and 
+DLX4 A2780 cell lines and sacrificed 4 weeks thereafter. Numbers of implants were 
counted on hematoxylin-eosin (HE) stained xenograft tissue sections from A) diaphragm and 
B) mesentery of mice. Bar, 2mm. 
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2. DLX4 promotes in vitro attachment of EOC cells to mesothelial cells  
       For this study, two EOC cell lines were used as models. For determining the effect of 
overexpressing DLX4, I used retrovirally transduced stable A2780 cell lines that express 
either empty vector or DLX4. For determining the effect of inhibiting DLX4, I used 2008, an 
EOC cell line that endogenously expresses DLX4 at a high level 
129
. Knockdown of DLX4 in 
2008 cells was carried out by using two shRNA plasmids that targeted two different sites 
within DLX4 (shDLX4-A and shDLX4-B). Overexpression of DLX4 in A2780 cell lines and 
knockdown of DLX4 in 2008 cell lines was assayed and quantified by qPCR analysis (not 
included) and flow cytometric analysis of intracellular staining of DLX4 (Figure 10). 
       Attachment of EOC cells within the peritoneal cavity is mediated via two primary 
mechanisms: attachment of EOC cells to the mesothelial cells lining the peritoneal cavity and 
attachment to the sub-mesothelial ECM 
23-26
. To determine whether DLX4 promotes 
attachment of EOC cells to peritoneal mesothelial cells, in vitro cell attachment assays were 
performed (Figure 11) by seeding equal numbers of GFP-expressing vector-control A2780 
cells and +DLX4 A2780 cells on to confluent monolayers of primary normal human 
mesothelial cells. Significantly higher number of +DLX4 A2780 cells were attached to the 
mesothelial cells as compared to the vector-control A2780 cells (P < 0.01) (Figure 12A). 
Conversely, 2008 cells in which DLX4 was knocked down (shDLX4-A and shDLX4-B) 
showed significantly reduced attachment to mesothelial cells as compared to control 2008 
cells  (empty vector and non-targeting) (P < 0.01) (Figures 12B, 12C). These findings 
indicate that DLX4 promotes attachment of EOC cells to mesothelial cells. 
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       To determine whether DLX4 promotes attachment of EOC cells to components of the 
sub-mesothelial ECM, in vitro cell attachment assays were performed by seeding equal 
numbers of GFP-expressing A2780 cells (empty vector and +DLX4) onto plates coated with 
ECM components, i.e. collagen I, fibronectin and laminin. No significant difference was 
observed between the numbers of vector-control and +DLX4 A2780 cells that attached to the 
components of the ECM (Figure 13). Similarly, no significant difference was observed in the 
numbers of DLX4-knockdown 2008 cells and control 2008 cells that attached to the ECM 
components (Figure 13). Together, these observations indicate that DLX4 promotes 
attachment of EOC cells to peritoneal mesothelial cells but not to the components of the 
ECM.   
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Figure 10. Overexpression of DLX4 in A2780 cells and knockdown of DLX4 in 2008 
cells 
Flow cytometric analysis of intracellular staining of DLX4 in (A) A2780 cell lines that 
express empty vector and DLX4 and in (B) 2008 cells that express empty vector, non-
targeting shRNA and shRNAs that target two different sites within DLX4 (shDLX4-A and 
shDLX4-B). Mean fluorescence intensities (MFI) of staining are indicated. 
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Figure 11. In vitro cell attachment assays 
Equivalent numbers of GFP-expressing EOC cells (shown in green) were seeded onto 
confluent monolayers of primary normal human mesothelial cells (shown in yellow) in 96-
well plates or on wells coated with collagen I, fibronectin or laminin. Cell attachment was 
assayed at one hour after seeding. Attached cells were viewed by immunofluorescence 
microscopy and counted in five random 200X microscopic fields per well. Each assay was 
performed in triplicate. 
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Figure 12. DLX4 promotes in vitro attachment of EOC cells to peritoneal mesothelial 
cells 
Equivalent numbers of GFP-expressing EOC cells were seeded onto confluent monolayers of 
peritoneal mesothelial cells. After one hour, numbers of attached cells were counted in 5 
random 200X microscopic fields per well. Numbers of (A) Attached vector-control and 
+DLX4 A2780 cells and (B) Control and DLX4-knockdown 2008 cells and (C) A 
representative picture of GFP-expressing 2008 cells attached to the monolayer of mesothelial 
cells. Shown in (A) and (B) are mean ± sd values of three independent attachment assays.   
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Figure 13. DLX4 does not mediate attachment of EOC cells to components of the ECM 
Equivalent numbers of vector-control and +DLX4 A2780 cells and control and DLX4-
knockdown 2008 cells were seeded on wells that were (A) uncoated or coated with (B) 
collagen I, (C) fibronectin and (D) laminin. Numbers of attached cells were counted after 1 
hour in five random 200X microscopic fields per well. Shown are mean ± sd values of three 
independent attachment assays.  
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3. DLX4 induces expression of CD44 in EOC cells 
       Attachment of EOC cells to the mesothelium lining the peritoneal cavity is mediated by 
various cell adhesion molecules such as P-cadherin, β1 integrin and CD44 24, 32, 33, 42. Because 
DLX4 is a transcription factor, DLX4 might promote attachment of EOC cells to mesothelial 
cells by inducing expression of these cell adhesion molecules. To investigate this possibility, 
I initially performed qRT-PCR to evaluate mRNA levels of candidate genes that encode cell 
adhesion molecules when DLX4 was overexpressed or knocked down. When DLX4 was 
overexpressed in A2780 cells, there was more than a 10-fold induction in CD44 mRNA 
levels as compared to levels in vector-control A2780 cells (P <0.001) (Figure 14A). 
However, there was no induction in mRNA levels for P-cadherin (CDH3) or β1 integrin 
(ITGB1) (Figures 14B, 14C). Conversely, when DLX4 was knocked down in 2008 cells, 
there was a significant reduction in CD44 mRNA levels (P < 0.01) (Figure 14A). No 
reduction in CDH3 or ITGB1 mRNA levels was observed after knockdown of DLX4 
(Figures 14B, 14C).  
       To further confirm the induction of CD44 by DLX4, I analyzed cell surface levels of 
CD44 protein by flow cytometry in vector-control and +DLX4 A2780 cells and in control 
and DLX4-knockdown 2008 cells. This analysis showed an induction in CD44 levels when 
DLX4 was overexpressed in A2780 cells (Figure 15A) and a reduction in CD44 levels when 
DLX4 was knocked down in 2008 cells (Figure 15B). These findings indicate that DLX4 
induces expression of CD44.  
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Figure 14. DLX4 induces expression of CD44 but not P-cadherin or β1 integrin 
A2780 cells that expressed empty vector or DLX4 and 2008 cells that expressed empty 
vector, non-targeting shRNA or shRNAs for DLX4 (shDLX4-A and shDLX4-B) were 
assayed by qRT-PCR for mRNA transcript levels of (A) CD44, (B) CDH3 (encoding P-
cadherin) and (C) ITGB1 (encoding β1 integrin). All samples were analyzed in triplicates in 
two independent experiments. Error bars represent standard deviation. 
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Figure 15. DLX4 induces expression of CD44 
Cell surface levels of CD44 were assayed by flow cytometry in (A) A2780 cells that 
expressed empty vector or DLX4 and  in (B) 2008 cells that expressed empty vector, non-
targeting shRNA or shRNAs against DLX4 (shDLX4-A and shDLX4-B). 
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4. DLX4 promotes attachment of EOC cells to peritoneal mesothelial cells via CD44 
       The glycoprotein CD44 is a major receptor for HA that is synthesized by peritoneal 
mesothelial cells 
52, 53
. Binding of CD44 to HA promotes attachment of EOC cells to 
mesothelial cells 
24, 53, 54
. Because my findings indicated that DLX4 promotes attachment of 
EOC cells to mesothelial cells and also induces CD44, I evaluated whether DLX4 promotes 
attachment of EOC cells to mesothelial cells via CD44.  In vitro cell-attachment assays were 
performed in which vector-control and +DLX4 A2780 cells were pre-incubated with a 
neutralizing Ab against CD44 prior to seeding onto mesothelial cells (Figure 16). The Ab 
was directed against an epitope close to the HA-binding domain of CD44 (Figure 16). 
Treatment with this neutralizing CD44 Ab blocked the attachment of +DLX4 A2780 cells to 
the peritoneal mesothelial cells, whereas treatment with control IgG had no effect (Figure 
17). In contrast, treatment with CD44 Ab had no significant effect on the ability of vector-
control A2780 cells to attach to mesothelial cells (Figure 17). This observation was 
consistent with my previous findings that vector-control A2780 cells express very low levels 
of CD44 (Figures 14A, 15). Together, these findings indicate that DLX4 promotes 
attachment of EOC cells to peritoneal mesothelial cells via CD44. 
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Figure 16. Mechanism of CD44-mediated attachment of EOC cells to mesothelial cells 
The cell adhesion molecule CD44, which is present on EOC cells, is a major receptor for HA 
that is synthesized by mesothelial cells 
52, 53
. Interaction of CD44 and HA facilitates 
implantation of EOC cells to mesothelial cells lining the peritoneal cavity 
24, 53, 54
. The CD44 
blocking Ab is directed against an epitope very close to the HA-binding domain of CD44 and 
prevents binding of CD44 to HA 
165
. 
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Figure 17. Neutralization of CD44 blocks the ability of DLX4-expressing EOC cells to 
attach to mesothelial cells 
GFP-expressing empty vector and +DLX4 A2780 cells were pre-incubated with CD44 
blocking Ab or normal IgG for 1 hour and then seeded onto confluent monolayers of 
mesothelial cells. Attachment of A2780 cells to the mesothelial monolayer was assayed at 1 
hour after seeding. Attached cells were counted in 5 random 200X microscopic fields. Shown 
are mean ± sd values of three independent attachment assays. 
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C. CONCLUSION 
       My studies in Chapter 3 demonstrate that overexpression of DLX4 in EOC cells induces 
CD44 expression and promotes attachment of EOC cells to mesothelial cells. Conversely, 
knockdown of DLX4 in EOC cells down-regulates expression of CD44 and reduces 
attachment of EOC cells to mesothelial cells. Furthermore, blocking CD44 in DLX4-
overexpressing EOC cells hinders their ability to attach to mesothelial cells. Together, these 
findings indicate that DLX4 promotes attachment of EOC cells to peritoneal mesothelial cells 
by inducing expression of CD44. The molecular mechanisms by which DLX4 induces 
expression of CD44 in EOC cells will be discussed in Chapter 4. 
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CHAPTER 4: MECHANISMS OF DLX4 IN PERITONEAL DISSEMINATION AND 
INFLAMMATORY SIGNALING IN EOC 
A. RATIONALE 
       Formation of ascites is one of the hallmarks of advanced-stage EOC 
56
. Ascites of EOC 
patients contains a wide variety of pro-inflammatory cytokines such as IL-8, IL-6 and IL-1β 
that stimulate tumor progression
63, 66, 67, 69, 72, 73
. Expression of these cytokines is associated 
with poor prognosis of EOC patients 
64
. However, the precise mechanisms by which 
inflammatory signaling in EOC contributes to peritoneal dissemination of tumors is poorly 
understood. 
      Studies in Chapter 3 demonstrated that DLX4 promotes the attachment of EOC cells to 
peritoneal mesothelial cells (Figure 12). My studies identified that this stimulatory effect of 
DLX4 is mediated by its ability to induce expression of CD44 on the surface of EOC cells 
(Figures 14A, 15, 17). In this chapter, the goal of my studies is to identify the mechanisms by 
which DLX4 induces expression of CD44 in EOC cells.  
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B. RESULTS 
1. DLX4 induces expression of IL-1β 
       Because DLX4 primarily functions as a transcription factor, I initially hypothesized that 
DLX4 might directly activate CD44 transcription. However, no potential DLX4 binding sites 
were identified in the CD44 promoter region by performing analysis of transcription factor 
binding sites (Genomatix). Several studies have demonstrated that the pro-inflammatory 
cytokine IL-1β promotes expression of CD44 in other inflammatory diseases such as 
arteriosclerosis and rheumatoid arthritis 
166, 167
. Other studies have identified that IL-1β levels 
are elevated in EOC patients 
70
. I therefore hypothesized that DLX4 induces expression of 
CD44 in EOC cells by stimulating production of IL-1β.  
       To determine whether DLX4 induces expression of IL-1β in EOC cells, I evaluated the 
expression of IL-1β when DLX4 was overexpressed or knocked down. IL1B mRNA levels 
were significantly higher in +DLX4 A2780 cells as compared to the vector control A2780 
cells (P < 0.001) (Figure 18A). Conversely, IL1B mRNA levels were significantly lower in 
DLX4-knockdown 2008 cells as compared to control 2008 cells (P < 0.001) (Figure 18A). 
Similarly, IL-1β protein levels were induced when DLX4 was overexpressed in A2780 cells 
and were reduced when DLX4 was knocked down in 2008 cells (Figure 18B). These results 
demonstrate that DLX4 induces expression of IL-1β in EOC cells. 
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Figure 18. DLX4 induces expression of IL-1β 
mRNA transcript levels of IL1B were assayed by qRT-PCR in (A) empty vector control and 
+DLX4 A2780 cells and (B) control (non-targeting) and DLX4-knockdown (shDLX4-A) 
2008 cells. Shown are mean ± sd values of three independent assays. 
Protein levels of IL-1β were assayed by ELISA in (C) empty vector control, +DLX4 and 
+DLX4 A2780 cells transfected with non-targeting shRNA and IL1B shRNA and (D) control 
(non-targeting), DLX4-knockdown (shDLX4-A) and DLX4-knockdown 2008 cells that were 
reconstituted with IL1B. Shown are mean ± sd values of three independent assays.  
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2. IL1B is a direct transcriptional target of DLX4 
       DLX4 is primarily known to function as a transcription factor. I therefore hypothesized 
that IL1B, the gene that encodes IL-1β, is a direct transcriptional target of DLX4 in EOC 
cells. A putative DLX4 binding motif was identified in the human IL1B promoter (Figure 
19A). Binding of endogenous DLX4 to the binding site detected on the IL1B promoter was 
demonstrated by chromatin IP assays in 2008 cells (Figure 19B).  
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Figure 19. DLX4 directly binds to IL1B promoter 
(A) Representation of the IL1B promoter with a putative DLX4 binding site (TATAAAT) 
located between nucleotides -353 to -359. (B) Chromatin immunoprecipitation analysis of the 
interaction of endogenous DLX4 in 2008 cells with the putative binding site identified on the 
IL1B promoter. Input DNA corresponds to 1% of the chromatin solution before 
immunoprecipitation. Immunoprecipitation was performed with DLX4 Ab and control IgG. 
Purified DNA was amplified with primers specific to IL1B promoter region and GAPDH. 
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3. DLX4 induces NF-κB transcriptional activity in EOC cells 
       IL-1β is known to induce canonical NF-κB signaling in tumors 74. Because my studies 
demonstrated that DLX4 induces expression of IL-1β in EOC cells, I investigated whether 
DLX4 promotes NF-κB transcriptional activity in EOC cells. To accomplish this, I assayed 
luciferase activity of a reporter construct driven by a synthetic promoter containing tandem 
repeats of NF-κB binding sites (Figure 20A) in cells in which DLX4 was overexpressed or 
knocked down. Overexpression of DLX4 in A2780 cells induced a 3-fold increase in NF-κB 
transcriptional activity (P < 0.001) (Figure 20B). Conversely, knockdown of DLX4 in 2008 
cells reduced NF-κB transcriptional activity by 50% (P < 0.01) (Figure 20B). 
       When canonical NF-κB signaling is activated, NF-κB transcription factors p65, p50 and 
c-Rel translocate to the nucleus, phosphorylate, form dimers and activate NF-κB target genes 
(Figure 5) 
77, 88
. High level of phosphorylated p65 in EOC is associated with advanced 
disease stage in patients 
85-87
. In subsequent studies, I evaluated levels of phosphorylated p65 
in EOC cells when DLX4 was overexpressed or knocked down by flow cytometric analysis 
of intracellular staining. Higher levels of phosphorylated p65 were detected in +DLX4 
A2780 cells as compared to the vector-control cells (Figure 21A). Conversely, lower levels 
of phosphorylated p65 were detected in DLX4-knockdown 2008 cells as compared to control 
2008 cells (Figure 21B). Together, these results demonstrate that DLX4 induces NF-κB 
transcriptional activity and levels of phosphorylated NF-κB transcription factor p65 in EOC 
cells. 
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Figure 20. DLX4 induces NF-κB signaling in EOC cells 
 (A) An illustration of the NF-κB-driven luciferase reporter construct containing tandem 
repeats of NF-κB transcriptional response elements. (B) Luciferase reporter assays were 
performed to assay NF-κB transcriptional activity in empty vector and +DLX4 A2780 cells 
and 2008 cells transfected with empty vector, non-targeting shRNA and shRNAs against 
DLX4 (shDLX4-A and shDLX4-B). Shown are relative luciferase activities in three 
independent experiments. Error bars represent standard deviation. 
2008 A2780 
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Figure 21. DLX4 induces levels of phosphorylated p65 in EOC cells 
Intracellular levels of phosphorylated p65 were assayed in (A) empty vector and +DLX4 
A2780 cells and (B) 2008 cells transfected with non-targeting shRNA and shRNA against 
DLX4 (shDLX4-A) by flow cytometry. 
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4. Induction of NF-κB signaling by DLX4 in EOC cells is mediated by IL-1β 
       Canonical NF-κB signaling activity in tumors is triggered by several cytokines including 
IL-1β 74. My studies have demonstrated that DLX4 promotes IL-1β expression and NF-κB 
transcriptional activity in EOC cells (Figures 18, 19, 20, 21). To determine whether induction 
of NF-κB activity in EOC cells by DLX4 occurs due to its induction of IL-1β, I inhibited 
expression of IL-1β by using shRNA against IL1B in +DLX4 A2780 cells. ELISA assays 
were performed to confirm that the shRNA reduced the IL-1β level in +DLX4 A2780 cells to 
the basal IL-1β level seen in vector control A2780 cells (Figure 18C). To evaluate NF-κB 
transcriptional activity, luciferase reporter assays were performed using the NF-κB driven 
reporter construct. Inhibition of IL-1β by shRNA in +DLX4 A2780 cells reduced the level of 
NF-κB transcriptional activity almost to the level detected in vector-control A2780 cells 
(Figure 22A). This finding indicates that the ability of DLX4 to stimulate NF-κB 
transcriptional activity is substantially mediated by its induction of IL-1β. 
       To confirm my findings, I investigated whether reconstitution of IL-1β can rescue the 
transcriptional activity of NF-κB when DLX4 is knocked down. To accomplish this, I 
transfected IL1B cDNA into DLX4-knockdown 2008 cells. ELISA assays were performed to 
confirm that transfection of IL1B cDNA in DLX4-knockdown 2008 cells restored the IL-1β 
level to a level comparable to that of control 2008 cells (Figure 18D). Reconstitution of IL-1β 
in DLX4-knockdown 2008 cells restored NF-κB transcriptional activity to a level 
comparable to that seen in control 2008 cells (Figure 22B). These results indicate that the 
induction of NF-κB transcriptional activity by DLX4 in EOC cells is mediated by its 
induction of IL-1β.   
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Figure 22. DLX4 induces NF-κB transcriptional activity in tumors via its induction of 
IL-1β 
Reporter assays using the NF-κB driven luciferase construct were performed to assay NF-κB 
transcriptional activity in (A) empty vector control A2780 cells, empty vector control A2780 
cells transfected with IκBα-DN, +DLX4 A2780 cells and +DLX4 A2780 cells transfected 
with IκBα-DN, non-targeting shRNA and shRNA against IL1B and (B) control (non-
targeting) 2008 cells, DLX4-knockdown 2008 (shDLX4-A) cells and DLX4-knockdown 
2008 cells after reconstitution with IL1B cDNA. Shown are relative luciferase activities in 
three independent experiments. Error bars represent standard deviation. 
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5. DLX4 induces CD44 in EOC cells in an IL-1β and NF-κB-dependent manner 
       My studies have demonstrated that DLX4 induces expression of 1) CD44 and 2) IL-1β in 
EOC cells (Figures 14A, 15, 18, 19). In subsequent experiments, I evaluated whether DLX4 
induces expression of CD44 in an IL-1β-dependent mechanism. To accomplish this, I 
evaluated expression of CD44 by flow cytometry when IL-1β was knocked down in +DLX4 
A2780 cells. Knockdown of IL-1β in +DLX4 A2780 cells reduced the CD44 level almost to 
the level seen in vector control cells (Figure 24). This finding indicates that the induction of 
CD44 by DLX4 is primarily mediated by its induction of IL-1β. 
       CD44 has been identified as a direct transcriptional target of NF-κB 168. Because my 
studies also demonstrated that DLX4 induces NF-κB transcriptional activity in EOC cells via 
IL-1β, I evaluated whether DLX4 induces CD44 expression in a NF-κB-dependent manner. 
To evaluate this, I inhibited NF-κB transcriptional activity in +DLX4 A2780 cells by 
expressing a dominant negative IκBα construct (IκBα-DN). This construct contains serine-32 
to alanine and serine-36 to alanine substitutions 
163
. IκBα-DN inhibits NF-κB signaling by 
retaining the NF-κB transcription factors in the cytoplasm. When the canonical signaling 
pathway is triggered by external stimuli, IKK normally phosphorylates IκBα at serine-32 and 
serine-36 
169
. This phosphorylation results in proteasomal degradation of IκBα and the 
release of NF-κB dimers which then translocate to the nucleus and transcriptionally activate 
target genes (Figure 5) 
169
. Mutations at serine-32 and serine-36 of IκBα prevents the 
phosphorylation and degradation of IκBα, thus retaining the NF-κB transcription factors in 
the cytoplasm and blocking NF-κB signaling (Figure 23) 169.  
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I initially confirmed that IκBα-DN inhibited NF-κB transcriptional activity in +DLX4 
A2780 cells by performing luciferase assays with the NF-κB-driven reporter construct 
(Figure 22A). In subsequent experiments, I evaluated whether DLX4 induces expression of 
CD44 in a NF-κB dependent manner. To determine this, I evaluated expression of CD44 by 
flow cytometry when NF-κB transcriptional activity was blocked with IκBα-DN in +DLX4 
A2780 cells. Flow cytometric analysis revealed that the CD44 level in +DLX4 A2780 cells 
was reduced by IκBα-DN almost to the CD44 level seen in vector control A2780 cells 
(Figure 24). Together, these findings demonstrate that DLX4 promotes expression of CD44 
in EOC cells via induction of IL-1β expression and NF-κB signaling.       
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Figure 23. Mechanism of IκBα-DN in abrogating NF-κB signaling 
The IκBα-DN construct contains substitution mutations of its two serine residues, 32 and 36. 
These mutations prevent the phosphorylation and degradation of IκBα by IKK complex. 
IκBα therefore retains NF-κB dimers in the cytoplasm and thereby blocks NF-κB 
transcriptional activity 
169
. 
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Figure 24. DLX4 induces expression of CD44 in EOC cells via IL-1β and NF-κB 
signaling 
Cell surface expression of CD44 was assayed by flow cytometry in empty vector control 
A2780 cells, +DLX4 A2780 cells and +DLX4 A2780 cells transfected with non-targeting 
shRNA, IL1B shRNA and IκBα-DN. 
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6. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the expression of 
CD44 
       My previous findings demonstrated that DLX4 induces CD44 expression in an IL-1β and 
NF-κB-dependent manner (Figure 24). To confirm my results, I evaluated whether 
reconstitution of IL-1β in DLX4-knockdown cells can rescue the expression of CD44. To 
accomplish this, I transfected DLX4-knockdown (shDLX4-A) 2008 cells with IL1B cDNA 
and analyzed CD44 levels by flow cytometry. Reconstitution of IL-1β in DLX4-knockdown 
2008 cells restored the CD44 level to a level comparable to that seen in control 2008 cells 
(Figure 25). This finding demonstrates that DLX4 induces CD44 expression via induction of 
IL-1β in EOC cells.  
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Figure 25. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the 
expression of CD44 
CD44 expression was assayed by flow cytometry in control 2008 cells (non-targeting), 
DLX4-knockdown 2008 (shDLX4-A) cells, and DLX4-knockdown 2008 cells after 
reconstitution of IL-1β. 
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7. DLX4 promotes EOC cell attachment to mesothelial cells via induction of IL-1β and 
NF-κB transcriptional activity 
       My studies demonstrated that DLX4 promotes the attachment of EOC cells to peritoneal 
mesothelial cells via induction of the cell adhesion molecule CD44 (Figure 17). My findings 
also demonstrated that DLX4 induces CD44 expression in EOC cells via induction of IL-1β 
(Figures 24, 25). In subsequent experiments, I evaluated whether DLX4 mediates the 
attachment of EOC cells to mesothelial cells in an IL-1β-dependent manner. To accomplish 
this, I performed in vitro cell attachment assays using GFP-expressing vector-control and 
+DLX4 A2780 cells and +DLX4 A2780 cells in which IL-1β was knocked-down. 
Knockdown of IL-1β in +DLX4 A2780 cells significantly inhibited the ability of these cells 
to attach to mesothelial cells (P < 0.01), whereas non-targeting shRNA had no effect (Figure 
26).  
      Because my studies demonstrated that DLX4 induces expression of CD44 in EOC cells 
by stimulating NF-κB transcriptional activity (Figure 24), I evaluated whether DLX4 
promotes attachment of EOC cells to mesothelial cells in an NF-κB-dependent manner. To 
accomplish this, I evaluated the ability of +DLX4 A2780 cells to attach to mesothelial cells 
when NF-κB was inhibited by IκBα-DN. Expression of IκBα-DN in +DLX4 A2780 cells 
reduced the ability of these cells to attach to mesothelial cells almost to the level seen in 
empty vector control A2780 cells (Figure 26). These results demonstrate that DLX4 
promotes EOC cell attachment to mesothelial cells in an IL-1β and NF-κB-dependent 
manner. These findings are consistent with my previous findings that DLX4 induces 
expression of CD44 in an IL-1β and NF-κB-dependent manner (Figures 24, 25).  
67 
 
 
 
Figure 26. DLX4 promotes EOC cell attachment to mesothelial cells via induction of IL-
1β and NF-κB 
The ability of EOC cells to attach to mesothelial cells was assayed by in vitro cell attachment 
assays using vector control A2780 cells, +DLX4 A2780 cells and +DLX4 A2780 cells 
transfected with non-targeting shRNA, IL1B shRNA and IκBα-DN. Shown are mean ± sd 
values of three independent attachment assays. 
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8. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the effect of DLX4  
       My previous findings demonstrated that DLX4 promotes attachment of EOC cells to 
peritoneal mesothelial cells in an IL-1β and NF-κB dependent manner (Figure 26). To further 
confirm these results, I evaluated the effect of reconstituting IL-1β in DLX4-knockdown 
EOC cells on their ability to attach to mesothelial cells. Reconstitution of IL-1β in DLX4-
knockdown 2008 cells rescued the ability of these cells to attach to mesothelial cells to a 
level that was comparable to that of control 2008 cells (Figure 27). This finding 
demonstrated that DLX4 primarily promotes attachment of EOC cells to mesothelial cells via 
its induction of IL-1β in EOC cells. 
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Figure 27. Reconstitution of IL-1β in DLX4-knockdown EOC cells rescues the effect of 
DLX4  
The ability of EOC cells to attach to mesothelial cells was assayed by in vitro cell attachment 
assays using control (non-targeting) 2008 cells, DLX4-knockdown (shDLX4-A) 2008 cells 
and DLX4-knockdown 2008 cells that were reconstituted with IL-1β. Shown are mean ± sd 
values of three independent attachment assays. 
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C. CONCLUSION 
       My studies in Chapter 4 provide important insights into the mechanisms by which DLX4 
promotes expression of CD44 and the ability of EOC cells to attach to peritoneal mesothelial 
cells. My studies have identified that DLX4 directly binds to and activates the gene encoding 
IL-1β in EOC cells. In addition, DLX4 induces NF-κB signaling in EOC cells via its 
induction of IL-1β. Furthermore, my studies demonstrate that inhibition of IL-1β and NF-κB 
signaling in +DLX4 A2780 cells significantly blocked the induction of CD44 and the ability 
of these cells to attach to mesothelial cells. Conversely, reconstitution of IL-1β in DLX4-
knockdown 2008 cells rescues the expression of CD44 and the ability of these cells to attach 
to mesothelial cells. In summary, my results indicate that DLX4 induces expression of IL-1β 
and NF-κB signaling in EOC cells which in turn induce expression of CD44 and the ability 
of EOC cells to attach to peritoneal mesothelial cells.   
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CHAPTER 5: DISCUSSION 
A. DLX4 PROMOTES ATTACHMENT OF EOC CELLS TO THE MESOTHELIUM 
LINING THE PERITONEAL CAVITY  
       The high lethality of EOC stems from rapid peritoneal involvement of the disease and 
late diagnosis. A key rate-limiting step in peritoneal metastasis of EOC is the attachment of 
EOC cells to the mesothelial lining of the peritoneal cavity. My studies in Chapter 3 
demonstrated that high expression of DLX4 in EOC cells promotes their attachment to the 
peritoneal mesothelial cells (Figure 12). On the other hand, overexpression of DLX4 did not 
promote attachment of EOC cells to the sub-mesothelial ECM components such as collagen 
I, fibronectin and laminin (Figure 13). My findings demonstrate that DLX4 mediates the 
attachment of EOC cells by inducing expression of the cell adhesion molecule CD44 
(Figures 14A, 15, 17). However, DLX4 did not induce expression of P-cadherin and β1 
integrin that also mediate EOC-peritoneal interactions (Figures 14B, 14C). The inability of 
DLX4 to induce expression of β1 integrin is consistent with the inability of DLX4 to mediate 
EOC cell attachment to the components of the ECM. Notably, blocking CD44 did not 
completely abrogate the attachment of EOC cells to mesothelial cells (Figure 17). 
Interactions between EOC cells and the peritoneum are known to be mediated by multiple 
cell adhesion molecules 
24, 32, 33, 42
. This explains the inability of the CD44 neutralizing Ab to 
completely abolish the attachment of +DLX4 EOC cells to mesothelial cells (Figure 17). 
These findings are consistent with other studies that have demonstrated that using a single 
neutralizing Ab against CD44, β1 integrin or P-cadherin was not sufficient to completely 
block EOC cell attachment to mesothelial cells 
24, 33, 42, 55
. A study by Strobel and colleagues 
also demonstrated that combining CD44 and β1 integrin blocking Abs resulted in an additive 
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inhibitory effect on EOC cell attachment 
33
. These findings indicate that multiple cell 
adhesion molecules need to be targeted simultaneously to effectively block attachment of 
EOC cells to mesothelial cells. The interplay between these different cell adhesion molecules 
can be a focus of future studies and provide insights for development of better targeted 
therapies.  
B. DLX4 PROMOTES CD44 EXPRESSION AND EOC-MESOTHELIAL CELL 
INTERACTIONS BY INDUCING IL-1β EXPRESSION AND ACTIVATING NF-κB 
SIGNALING 
       IL-1β is a pleiotropic cytokine that contributes to inflammation in numerous pathological 
conditions such as cancer, arteriosclerosis, type II diabetes, rheumatoid arthritis, 
osteoarthritis and cardiovascular disorders 
170
. Although many other  cytokines mediate 
inflammatory signaling, IL-1β is known as the ‘gatekeeper of inflammation’ 171. My studies 
in Chapter 4 demonstrated that high expression of DLX4 in EOC cells induces expression of 
IL-1β by direct transcriptional activation (Figures 18, 19). Inhibition of IL-1β in +DLX4 
EOC cells resulted in a down-regulation of CD44 expression and reduced the ability of EOC 
cells to attach to mesothelial cells (Figures 24, 26). Conversely, reconstitution of IL-1β in 
DLX4-knockdown EOC cells restored CD44 levels and the ability of EOC cells to attach to 
mesothelial cells (Figures 25, 27). The ability of DLX4 to promote CD44 expression and 
attachment of EOC cells to mesothelial cells therefore, primarily occurs via its induction of 
IL-1β in EOC cells. A study by Foster and colleagues has demonstrated that induction of 
CD44 by IL-1β in vascular smooth muscle cells contributes to pathogenesis of 
arteriosclerosis 
167
. Another study by Campo and colleagues has demonstrated that IL-1β and 
HA induce CD44 expression and inflammatory signaling in rheumatoid arthritis 
166
. My 
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study is the first to demonstrate the significance of IL-1β in inducing CD44 expression in 
controlling cell-cell interactions that mediate metastasis of EOC.  
       IL-1β induces the NF-κB signaling pathway in a wide variety of physiological and 
pathological conditions  
77
. My findings in Chapter 4 demonstrated that high expression of 
DLX4 stimulates NF-κB signaling in EOC cells via its induction of IL-1β (Figures 20, 21, 
22). Moreover, inhibition of NF-κB signaling in +DLX4 EOC cells down-regulated CD44 
levels and decreased the ability of EOC cells to attach to mesothelial cells (Figures 24, 26). 
These results indicate that DLX4 induces expression of CD44 and the attachment of EOC 
cells to peritoneal mesothelial cells by activating NF-κB signaling in EOC cells. My 
functional studies therefore support findings of clinical studies that identified a strong 
correlation between activated NF-B signaling in EOC and advanced disease stage 84-87.  
       Substantial evidence indicates that NF-κB activates expression of a wide variety of target 
genes that promote tumor cell survival, tumor angiogenesis and metastasis 
74
. For example, 
NF-κB promotes tumor angiogenesis by induction of pro-angiogenic growth factors such as 
VEGF, IL-6 and IL-8 in multiple types of tumors including EOC 
69, 172-174
. NF-κB can also 
promote epithelial-mesenchymal transition (EMT) by transcriptional upregulation of Twist 1 
175
. However, NF-κB is also known to have pro-apoptotic functions in certain cell types and 
conditions. For example, a study by Ryan and colleagues demonstrated that p53 can induce 
tumor cell death via activation of MEK1 and NF-κB signaling 176. Another study by Rocha 
and colleagues demonstrated that p53 downregulates cyclin D1 expression by inhibiting Bcl-
3, a member of the IκB family of proteins and a transcriptional co-activator for NF-κB 
transcription factor p52 
177
. These authors found that p53 induces formation of p52/histone 
deacetylase1 (HDAC1) repressor complexes, which replaces Bcl-3/p52 activator complexes 
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and thereby represses transcription of the gene encoding cyclin D1 
177
. A study by Yang and 
colleagues demonstrated that NF-κB signaling can have dual functions in EOC 178. On one 
hand, NF-κB has a tumor-suppressive functions by sensitizing EOC cells to apoptosis 
induced by paclitaxel and carboplatin. On the other hand, NF-κB has tumor-promoting 
functions in aggressive forms of EOC and contributes to chemoresistance 
178
. Because DLX4 
is expressed in advanced-stage and aggressive forms of EOC 
129
, my findings that induction 
of NF-κB signaling in DLX4-expressing EOC cells contributes to EOC progression are 
consistent with other studies that have identified a tumor-promoting role of NF-κB in 
advanced stage tumors.  
C. MULTIPLE ROLES OF DLX4 IN TUMOR PATHOGENESIS  
       My studies demonstrated that DLX4 induces expression of CD44 in EOC cells and 
promotes their attachment to mesothelial cells by inducing expression of IL-1β and NF-κB 
signaling (Figure 24, 26). However, by inducing IL-1β and NF-κB signaling, DLX4 could 
also stimulate a variety of other processes that promote progression of EOC. IL-1β has been 
reported to confer chemoresistance in pancreatic carcinoma cell lines 
179
. IL-1β also 
promotes tumor vascularization in lung cancers via induction of VEGF 
180
. IL-1β and TNF-α 
have been implicated in the induction of hypoxia inducible factor-1 (HIF-1) expression in 
hepatoma cells, which in turn induces VEGF and tumor angiogenesis 
181
. IL-1β, TNF-α and 
interferon-γ (IFN-γ) also stimulate expression of inducible nitric oxide synthase (iNOS) in 
various tumors 
182
. Nitric oxide, the product of iNOS, plays an important role in promotion of 
tumor angiogenesis by regulating HIF-1 and VEGF expression in tumors 
182
. Previous studies 
from our laboratory have demonstrated that DLX4 promotes EOC growth and angiogenesis 
by inducing expression of pro-tumorigenic factors such as VEGF and fibroblast growth 
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factor-2 (FGF-2) 
129
. Since expression of VEGF is activated by IL-1β and NF-κB signaling, 
my findings could explain the mechanism by which DLX4 induces VEGF expression and 
angiogenesis in EOC. 
       In addition to EOC, DLX4 is overexpressed in other types of solid tumors including 
breast and prostate cancers and in leukemias 
153, 155, 156, 158, 162
. The mechanisms by which 
DLX4 promotes progression of other types of tumors are not well understood. DLX4 is 
highly expressed in inflammatory breast cancers (IBCs), an aggressive subtype of breast 
cancer 
156
. My findings that DLX4 stimulates NF-κB signaling raise the possibility that 
DLX4 might also promote the aggressive behavior of IBCs. Some specific sets of homeobox 
genes have been found to act similarly in different types of tumors. One such example is 
HOXB7 which is overexpressed in EOC, melanoma and breast cancers 
122, 125, 126
. Several 
studies have demonstrated that HOXB7 promotes tumor growth and angiogenesis via 
upregulation of FGF-2 in these different types of tumors 
122, 125-127
.  On the other hand, other 
sets of homeobox genes act differently in different types of tumors. One example is HOXA9. 
HOXA9 has been demonstrated to have tumor promoting properties in EOC and 
glioblastomas 
136-139
. Expression of HOXA9 in EOC cells induces stromal cells to produce 
growth factors that support tumor growth 
137
. HOXA9 also promotes peritoneal 
dissemination of EOC by inducing the cell adhesion molecule P-cadherin 
139
. In contrast, 
HOXA9 has tumor-suppressive functions in breast cancers 
183
. HOXA9 has been reported to 
prevent progression of breast cancers by maintaining BRCA1 expression 
183
. My study has 
shown that high expression of DLX4 promotes inflammatory signaling and peritoneal 
dissemination of EOC via induction of IL-1β and NF-κB signaling. However, it remains to 
be determined whether DLX4 promotes progression of other types of tumors by stimulating 
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NF-κB signaling. Further investigation of the role of DLX4 in controlling NF-κB signaling in 
tumors will provide insights into the therapeutic targeting of the NF-κB signaling pathway. 
D. THERAPEUTIC IMPLICATIONS 
       Because DLX4 is a transcription factor that shares functional domains in common with 
other family members, it may be difficult to specifically target DLX4 for therapeutic 
purposes. On the other hand, inhibiting the downstream effectors of DLX4, i.e. IL-1β and the 
NF-κB signaling pathway may be a promising strategy. Several IL-1 therapeutics such as IL-
1 receptor antagonists, anti-IL-1 monoclonal Abs, soluble IL-1 receptor II (IL-1RII), IL-1β 
converting-enzyme (ICE) inhibitors and IL-1 ligand traps are being currently used in the 
treatment of rheumatoid arthritis 
184
. Such novel treatments could be applied for the treatment 
of cancer. In addition, agents that target the NF-κB signaling pathway could be an effective 
therapeutic strategy 
185
. For example, Bortezomib is a proteasome inhibitor that blocks NF-
κB signaling and is already in use for treatment of multiple myeloma and mantle cell 
lymphoma 
186
. Moreover, inhibition of CD44-HA interaction and EOC cell adhesion using 
CD44 monoclonal Abs or small molecule inhibitors could be another possible strategy for 
treatment of advanced-stage EOC 
187, 188
. Further studies examining the effect of these 
inhibitors in EOC will provide insights into strategies for effective treatment for advanced 
stages of this disease. 
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E. CONCLUSION 
       The high mortality of EOC primarily stems from the rapid peritoneal dissemination of 
the disease and the inability to detect the disease at an early stage. The mechanisms that 
control tumor-peritoneum interactions are not well understood. My study supports a model in 
which DLX4 promotes CD44-mediated peritoneal attachment of EOC via induction of the 
pro-inflammatory cytokine IL-1β and activation of NF-κB signaling (Figure 28). Further 
study of the regulation and function of the NF-κB signaling pathway and its activating 
ligands and downstream effectors could yield important insights into possible therapeutic 
targets and new treatment strategies for patients with advanced-stage and chemoresistant 
EOC.  
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Figure 28. Model of the mechanism by which DLX4 promotes intraperitoneal 
dissemination of EOC 
DLX4 promotes CD44-mediated attachment of EOC cells to the peritoneal mesothelial cells 
by inducing expression of IL-1β and activating NF-κB signaling 
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